Collegium Ramazzini Statement on the Unjustified Dismissal of Dr. Daniele Mandrioli
Keywords:
collegium Ramazzini, statementAbstract
The Collegium Ramazzini has been informed by the President of the Ramazzini Institute that she and the Institute’s Board of Directors have made the decision to relieve Dr. Daniele Mandrioli MD, PhD of his duties as Director of the Cesare Maltoni Cancer Research Center.
The Collegium Ramazzini is deeply distressed by this decision. We are especially distressed by the closed,
non-transparent, and secretive way in which the decision was made. The President and Directors have offered
no rationale for their decision other than to say that it was undertaken in the context of a ‘reorganization’ of the
Ramazzini Institute.
A key feature of the research of the Ramazzini Institute from its inception has been its independence of
vested interest from the companies that produce and sell toxic products such as asbestos, tobacco, aspartame, and
pesticides. The independence and the high scientific quality of this research, which has saved the lives of millions
of people around the world, has been a source of great pride to the Collegium Ramazzini and to City of Bologna.
The Collegium Ramazzini is concerned that this decision - made for unclear motives - poses a grave threat
to the independence and scientific integrity of the Ramazzini Institute and the Cesare Maltoni Cancer Research
Center. Moreover, this action undermines the reputation of the City of Bologna as a seat of science, a university
city, a center of enlightenment, that has been recognized for centuries for its support of independent scientific
enquiry.
References
.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Collegium Ramazzini
This work is licensed under a Creative Commons Attribution 4.0 International License.
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.
How to Cite
